A cell model for discovering biomarkers and druggable targets for pulmonary fibrosis May 1, 2023 - Nov 30, 2024
Phase 2a, Randomised, Double-Blind, Placebo-Controlled, Two-Part Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetic Profiles of Inhaled Doses of NOC-100 in Adult Participants with Chronic or Acute Cough Nov 1, 2021 - Dec 31, 2023
Randomised, double-blind, parallel group. Phase 2b dose-finding, efficacy and safety study of 12-week twice daily oral administration of BAY 1817080 compared to placebo in the treatment of refractory and/or unexplained chronic cough (RUCC) Jan 1, 2021 - Feb 28, 2022
An exploratory sub-study to protocol GLPG1690-CL-303 to assess lung function in patients with idiopathic pulmonary fibrosis, using hyperpolarized xenon magnetic resonance imaging Nov 1, 2019 - Apr 30, 2022
TR12: A Phase 2, Double-blind, Randomized, Placebo-controlled, Two-Treatment, Two-Period Crossover Efficacy and Safety Study in Idiopathic Pulmonary Fibrosis with Nalbuphine ER Tablets for the Treatment of Cough Oct 1, 2019 - Dec 31, 2022
ATLAS: A Randomized Open-Label, Phase 1b Study of the Safety of Pirfenidone Solution for Inhalation (AP01) in Patients with Idiopathic Pulmonary Fibrosis Jun 1, 2019 - Jan 31, 2022
SCENIC: Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study with Inhaled RVT-1601 for the Treatment of Persistent Cough in Patients with Idiopathic Pulmonary Fibrosis (IPF) May 1, 2019 - Jan 31, 2022
ISABELA1: A Phase 3, randomized, double-blind, parallel-group, placebocontrolled multicenter study to evaluate the efficacy and safety of two doses of GLPG1690 in addition to local standard of care for minimum 52 weeks in subjects with idiopathic pulmonary fibrosis. Aug 1, 2019 - Dec 31, 2022
RELIEF: A Randomised, Double-blind, Placebo-Controlled, Crossover, Dose Escalation Study of BLU-5937 in subjects with Unexplained or Refractory Chronic Cough Jun 1, 2020 - Dec 31, 2020
BICS: A randomised, double-blind placebo controlled trial of the effectiveness of the beta-blocker bisoprolol in preventing exacerbations of chronic obstructive pulmonary disease Jun 1, 2017 - May 31, 2022
